Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

UMN Pharma Inc Lowers Consolidated Full-year Outlook for FY 2013


Friday, 24 May 2013 03:00am EDT 

UMN Pharma Inc announced that it has lowered its consolidated full-year outlook for revenue from JPY 400 million to JPY 24 million, operating profit from a loss of JPY 1,250 million to a loss of JPY 1,556 million, ordinary profit from a loss of JPY 1,400 million to a loss of JPY 1,697 million, net profit from a loss of JPY 1,000 million to a loss of JPY 1,306 million and earning per share from a loss of JPY 138.79 to a loss of JPY 177.60, for the fiscal year ending December 2013. The Company lowered the outlook due to the decreased sales, among others. 

Company Quote

3075.0
 --
18 Dec 2014